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Background: Neuroinflammation is increasingly recognized as contributing to the pathogenesis of depression. Key
inflammatory markers as well as kynurenic acid (KYNA) and quinolinic acid (QUIN), both tryptophan metabolites,
have been associated with depressive symptoms and suicidality. The aim of the present study is to investigate the
peripheral concentration of cytokines and tryptophan and kynurenine metabolites in patients with unipolar
treatment-resistant depression before and after electroconvulsive therapy (ECT), the most effective treatment for
depression.
Methods: Cytokines in plasma from patients with major depressive disorder (MDD; n = 19) and healthy volunteers
(n = 14) were analyzed with electrochemiluminescence detection. Tryptophan and kynurenine metabolites were
detected with high-performance liquid chromatography (HPLC) and LC/MS. KYNA was analyzed in a second healthy
control cohort (n = 22).
Results: Patients with MDD had increased plasma levels of interleukin (IL)-6 compared to healthy volunteers
(P < 0.05). We also found an altered kynurenine metabolism in these patients displayed by decreased plasma levels
of KYNA (P < 0.0001) as well as a significantly increased QUIN/KYNA ratio (P < 0.001). Plasma levels of tryptophan,
kynurenine, and QUIN did not differ between patients and controls. Treatment with ECT was associated with a
significant decrease in the plasma levels of tryptophan (P < 0.05), kynurenine (P < 0.01), and QUIN (P < 0.001),
whereas plasma levels of KYNA did not change. The QUIN/KYNA ratio was found to significantly decrease in
ECT-treated patients (P < 0.05). There was a significant inverse correlation between symptom severity and
kynurenine levels at baseline (r = −0.67, P = 0.002).
Conclusions: This study confirms an imbalanced kynurenine pathway in MDD supporting the hypothesis of a
netstimulation of N-methyl-D-aspartic acid (NMDA) receptors in the disorder. Treatment with ECT profoundly
decreased QUIN, an NMDA-receptor agonist previously suggested to be implicated in the pathogenesis of
depression, an effect that might have bearing for the good clinical outcome of ECT.
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Major depressive disorder is a severe, life-threatening
psychiatric illness, exposing the patient to direct risks,
such as increased mortality due to cardiovascular dis-
ease, stroke, and alcohol abuse disorders. It is a leading
cause of disability affecting millions of people worldwide
and often causing chronic recurrent symptoms and pro-
found socioeconomic burden [1]. With depression also
follows a high risk of suicidal behavior, including at-
tempts and completed suicides. More than 800,000
people die due to suicide every year, and it is estimated
that for each adult who dies of suicide, there may have
been more than 20 others attempting suicide [2]. De-
pression has been ranked as the fourth leading cause of
disability worldwide by the World Health Organization
[3], and the lifetime prevalence in high-income countries
is 14 % [4].
The etiology of depression is still poorly understood, but
recent hypotheses suggest that its development involves
the activation of the innate immune system as well as
alterations in glutamate excitotoxicity [5–7]. Indeed, in-
creased concentrations of pro-inflammatory cytokines,
chemokines, and acute-phase proteins have been observed
in depressed patients. Increased circulating levels of inter-
leukin (IL)-6 and C-reactive protein are the most fre-
quently observed findings [8–10], but also, increased
central levels of IL-6 have been described [11, 12].
Although evidence of immune activation in depression
is emerging, the functional relationship to aberrant brain
neurotransmission and behavior still needs to be estab-
lished. Recently, activation of the kynurenine pathway
has been suggested as a specific pathogenic mechanism
that can explain this link [13–16]. Tryptophan degrad-
ation along this pathway produces several neuroactive
compounds, such as quinolinic acid (QUIN), an N-methyl-
D-aspartic acid (NMDA)-receptor agonist, and kynurenic
acid (KYNA), a blocker of the NMDA receptor and the
alpha7* nicotinic receptor (α7nAChR) [17]. Importantly,
pro-inflammatory cytokines, especially interferon-γ but
also IL-1β and IL-6, are potent inducers of indoleamine
2,3 dioxygenase (IDO-1) and tryptophan 2,3-dioxygenase
(TDO2), the two main enzymes regulating the first step of
the kynurenine pathway [18–21]. We, and others, have
previously shown that KYNA is elevated in the cerebro-
spinal fluid (CSF) and postmortem brain of patients with
psychotic disorders, such as schizophrenia and bipolar
disorder [22–28]. With regard to depression, excessive
NMDA-receptor signaling, tentatively through an in-
creased QUIN/KYNA ratio, has been suggested [14, 15].
Thus, in a recent study, we found that CSF levels of QUIN
were elevated in suicide attempters, and approximately
half of these patients suffered from major depression. CSF
QUIN was also correlated to CSF IL-6, indicating that
inflammation had triggered the synthesis of QUIN [14].Enhanced QUIN density has also been observed in the an-
terior cingulate gyrus of suicide victims [29]. Studies of
peripheral kynurenines in depression are not totally uni-
form, but similar to CSF studies, they point to an over-
weight of the toxic branch of the kynurenine pathway.
Thus, decreased plasma levels of KYNA [30, 31] and re-
duced plasma KYNA/QUIN and/or KYNA/3-hydroxyky-
nurenine (3-HK) ratios [32, 33] have been described in
depressed patients.
Since the 1950s, more or less all medications used for
depression target the monoaminergic system. The effi-
cacy of these medications is limited, and a substantial
proportion of patients experience residual symptoms
and persistent functional impairments or do not even re-
spond to treatment [34]. Typically, they also have a lag
time of several weeks [35], which is not satisfactory for
acute suicide ideation and severe depression. Therefore,
there is a major need to develop more effective therapies
to treat these disorders and/or their deleterious phases
by exploring other therapeutic approaches. An alternative
treatment for more severe major depression, treatment-
resistant depression, or suicidality is electroconvulsive
therapy (ECT). This therapy triggers a brief seizure, by ap-
plying electric currents that pass through the brain.
Despite the longstanding use of ECT, the exact neuro-
biological mechanisms underlying its efficacy are not yet
understood. Studies have primarily focused on the changes
in neurophysiology [36], neuroendocrine [37], and neuro-
genesis [38] after ECT treatment. However, only a limited
number of studies have addressed functioning of the im-
mune system in relation to ECT for depression.
The aims of the present study are to analyze cytokines
and kynurenines in treatment-resistant patients with
major depressive disorder (MDD) and healthy controls
and to relate these biomarkers to depression scores. We
also investigate whether ECT influences cytokines and




Nineteen patients diagnosed with MDD (11 males and 8
females) and prescribed ECT by their treating psych-
iatrist were included in the study. Venipuncture failed in
three patients at blood sampling after the third ECT ad-
ministration, and one patient was excluded due to upper
respiratory tract infection at the time of ECT treatment.
Data from these patients are included only at baseline.
The diagnosis was established by a psychiatrist using the
complete clinical presentation and a Mini-International
Neuropsychiatric Interview (MINI) [39] or by two psy-
chiatrists using the Montgomery-Åsberg Depression
Rating Scale (MADRS) [40]. MADRS was available for
18 patients at baseline and for 15 patients after three
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ted, subjected to ECT within 3 months prior to the
study, or not able to understand the verbal and written
information were excluded from the study. Eighteen pa-
tients had been adequately treated with oral antidepres-
sant but had not responded, and one was treatment
naïve. The concomitant drugs given were lithium (n = 1),
antipsychotics (n = 3), benzodiazepines (n = 8), and hyp-
notic drugs (n = 12).
Healthy volunteers and healthy controls
Cohort 1 Fourteen male volunteers were mainly re-
cruited among medical students, hospital staff members,
and their relatives. They were all in good physical health
and subjected to a medical check-up including labora-
tory tests (electrolytes, blood, thyroid, kidney, and liver)
and a physical examination. All volunteers were free
from medication for at least 1 month and free from any
form of substance abuse, except for smoking (three
healthy volunteers were smokers). Volunteers were sub-
jected to a semi-structured interview using the Struc-
tured Clinical Interview for DSM-IV Disorders [41] or
interviewed by a psychiatrist to exclude mental illness.
None of them had a family history of major psychosis,
major depression, or suicide in first- or second-degree
relatives, and they were all found to be free from current
signs of psychiatric morbidity or difficulties in social ad-
justment at the time of sampling.
Cohort 2 Population-based healthy controls were ran-
domly selected by Statistics Sweden (SCB) and contacted
by mail with a request for them to contact the study
nurse if interested in participating in the study. Follow-
ing a preliminary telephone screening, eligible persons
were interviewed by experienced psychiatrists. Apart
from psychiatric disorders and drug abuse, other ex-
cluded diagnoses were neurological conditions other
than mild migraines, untreated endocrinological disor-
ders, autoimmune disorders, pregnancy, and a family
history of schizophrenia or bipolar disorder in first-
degree relatives. Additionally for this study, individuals
who had inflammatory disorders were excluded.
Twenty-two such healthy controls were selected to
match the probands, based on sex and age.
ECT and plasma sampling
Patients were treated with ECT in the morning after at
least 6 h of fasting at the University Hospital, Linköping,
and at the Department of Clinical and Experimental
Medicine, Division of Psychiatry, Faculty of Health Sci-
ences, Linkoping University, Sweden. All patients received
atropine before anesthesia was induced with thiopental.
Muscle relaxation was induced with succinylcholine. The
patients were ventilated with 100 % oxygen. A Mectaspectrum 5000Q device was used to give right unilateral
ECT treatments with ultrabrief or brief pulse waves, and
dosage was adjusted by age, sex, and outcome. Electroen-
cephalography and a stopwatch were used to monitor the
seizures. All plasma samples were collected between 8 and
11 am and after a night of fasting.
Policy and ethics
This study was conducted in accordance with the latest
Helsinki Protocol. The Ethics Committee of the Medical
Faculty of Linköping University, Sweden; the Swedish
Medical Products Agency; the Regional Ethics Commit-
tee in Stockholm; and the Swedish Data Inspection
Board approved the study. All patients and healthy vol-
unteers included received verbal and written information
and gave their written informed consent. AstraZeneca
did neither influence nor sponsor the clinical research
performed at Linköping University or Karolinska Institutet.
These data arise from a sample collection, not from a pro-
spective trial, and is therefore not recorded in any clinical
trial registry.
Biochemical analyses
Blood samples were collected in heparinized tubes from
overnight-fasting healthy volunteers, healthy controls,
and patients. In patients, blood samples were collected
before the first ECT and after the third ECT. Blood sam-
ples were centrifuged at (1438×g, 10 min), and plasma
was collected and stored at −70 °C until analysis. All
tryptophan metabolites were successfully detected in all
plasma samples with an exception for KYNA and kynur-
enine not detected in one sample. In the second cohort
of controls, only KYNA was analyzed.
Analysis of KYNA
Plasma samples were centrifuged at 21,000×g, for 5 min
after deproteination with an equal volume of perchloric
acid (0.4 M, containing 0.1 % sodium metabisulfite and
0.05 % EDTA). The centrifugation procedure was re-
peated followed by an additional 70 % perchloric acid
(10 % by volume). Analysis of KYNA was measured by
high-performance liquid chromatography (HPLC) with
fluorescence detection, and the method has been out-
lined in detail previously [26]. Briefly, 50 μL of the
deproteinized supernatant was injected to a ReproSil-
Pur C18 reversed-phase column (4 × 150 mm; Dr.
Maisch GmbH, Ammer-buch, Germany) using a fluores-
cence detector (Jasco Ltd., Hachioji City, Japan) with an
excitation wavelength of 344 nm and emission wave-
length of 398 nm (18-nm bandwith). A mobile phase
containing 50 mM sodium acetate (pH 6.2) and 7 %
acetonitrile was pumped through the reverse-phase col-
umn at a flow rate of 0.5 mL/min. Zinc acetate (0.5 M)
was delivered post-columnar by a Pharmacia P-500
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10 mL/h. The retention time of KYNA was approxi-
mately 7.5 min and was clear from other peaks with
an exception for one sample that could not be distin-
guished due to an unknown peak at the same reten-
tion time. The sensitivity of the system was verified
by analysis of a standard mixture of KYNA with con-
centrations from 0.25 to 30 nM, which resulted in a
linear standard plot. The lower detection limit of the
system was set to 0.625 nM. Some samples were ana-
lyzed in duplicates and confirmed that the intra-
individual variation did not exceed 5 %.
Analysis of tryptophan, kynurenine, and QUIN
Plasma and standard samples (100 μL) were diluted two
times with internal standard solution in 5 % formic acid
and filtered at 2500×g for 60 min at 10 °C using 10-kDa
Ultracel®-10 filter plates from Millipore. Internal Standards
(IS) were added to each standard and plasma sample.
Metabolites were purchased from Sigma-Aldrich (QUIN,
kynurenine, and 2H5-tryptophan) and Synfine Research
Inc., Ontario, Canada (13C3
15N1-QUIN).
After centrifugation, 7.5 μL of the filtrate was injected
using a Waters Acquity HPLC system equipped with a
SymmetryShield™ RP18 2.1 × 100 mm, 3.5-μm particle
column. The detection was performed using a Waters
Xevo TQ triple quadrupole mass spectrometer operating
in positive ionization MS/MS configuration. The mobile
phase was run at a flow rate of 300 μL/min and con-
sisted of 2.1 % formic acid in MilliQ water (A phase)
and acetonitrile (B phase) starting with 5 % acetonitrile
for 2 min following gradient elution, total run time of
10 min. The formic acid and acetonitrile were purchased
as MS-grade from Sigma-Aldrich. The mass spectrom-
eter was tuned for each analyte and set at a capillary
voltage of 3.0 V, cone voltage of 16 V, source
temperature of 150 °C, desolvation temperature of 350 °C,
and desolvation gas flow of 650 L/h. Mass spectral
transition for QUIN was m/z 168 > 106, kynurenine
209 > 146, and tryptophan 205 > 118 using collision
energies of 14, 18, and 24 eV, respectively. Retention
times for QUIN, kynurenine, and tryptophan were
1.2, 1.7, and 3.6 min, respectively.
Cytokine analyses
IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, tumor necrosis
factor (TNF)-α, interferon (IFN)-γ, and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were
quantified in plasma using a customized Human Ultra-
Sensitive 9-Plex Kit (MesoScale Discovery, Gaithersburg,
MD, USA) in 2013. The assays were analyzed as per
the manufacturers’ protocol (http://www.mesoscale.com).
Intra-assay coefficient of variation was below 25 % for all
cytokines presented. The limits of detection (LOD) wereIL-1β (0.36 pg/mL), IL-2 (0.35 pg/mL), IL-6 (0.27 pg/mL),
IL-8 (0.09 pg/mL), IL-10 (0.21 pg/mL), IL-12p70 (1.4 pg/
mL), TNF-α, (0.5 pg/mL), IFN-γ (0.74 pg/mL), and GM-
CSF (0.20 pg/mL).
Statistical analysis
All values are given as median and with interquartile
range (IQR). Nonparametric tests were used due to a
small sample size in each group (D’Agostino & Pearson
omnibus normality test). Differences regarding plasma
levels of cytokines and kynurenine metabolites between
healthy controls and patients with depression were
established using Mann-Whitney U test. Wilcoxon
matched-pairs signed-rank test was used when comput-
ing differences in MADRS scores, plasma concentrations
of cytokines, and kynurenine metabolites in patients be-
fore and after treatment with ECT. All correlation ana-
lyses were performed using a Spearman rank correlation
analysis. Significance was assumed for all values where
P < 0.05. All reported P values are two sided, and all ana-
lyses were corrected for age and gender when appropri-
ate. The analyses were done using SPSS® Statistics 20.0
(IBM Inc., Chicago, IL, USA) or Prism® 6.0 (GraphPad
Software Inc., La Jolla, CA).
Results
Demographics
In the present study, 19 patients (11 males and 8 females),
14 (all males) healthy volunteers, and 22 healthy controls
(13 males and 9 females) were included. The median age
was significantly higher in patients (41.0 years, IQR 25.0–
54.0 years) than in healthy volunteers (24.0 years, IQR
23.0–26 years, P < 0.004, Mann-Whitney U test) but simi-
lar to the healthy controls (40.5 years, IQR 34.8–60.5 years).
Patients were clinically evaluated with MADRS before
ECT, and the median MADRS score for these patients was
37.0 (IQR 28.8–44.3). Following three ECT administra-
tions, MADRS significantly decreased to 20.5 (IQR 14.0–
26.5, P < 0.001).
Cytokines in patients with MDD and healthy male
volunteers
Plasma levels of IL-6, IL-8, IL-10, and TNF-α were de-
tected in 13 of the 14 healthy male volunteers and in all
19 unipolar depressed patients with an exception for IL-
10 and IL-6 that was not detected in one patient with
MDD. The other cytokines analyzed were undetectable
(IL-2) or found to be very close to the detection limit of
the assay. Thus, IL-1β, IFN-γ, GM-CSF, and IL-12p70
were only detected in a limited number of samples and
therefore not further analyzed. Plasma IL-6 concentra-
tion was elevated in patients with MDD (1.46 pg/mL,
IQR 0.80–4.0 pg/mL, n = 18) compared to healthy male
volunteers (0.85 pg/mL, IQR 0.72–1.25 pg/mL, n = 13;
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IL-6 was still significantly increased in male patients with
MDD ([n = 11] 1.46 pg/mL, IQR 1.17–4.68 pg/mL vs. the
healthy male volunteers [n = 13] 0.85 pg/mL, IQR 0.72–
1.25 pg/mL; P = 0.0029). No correlation between age and
IL-6 was observed in either patients (ρ = −0.45; P = 0.86)
or in healthy male volunteers (ρ = −0.14; P = 0.63). We
could not find any differences in the plasma levels of the
other cytokines detected (IL-8, IL-10, and TNF-α) be-
tween patients with MDD and healthy male volunteers
(Fig. 1b–d).
Tryptophan and kynurenines in patients with MDD,
healthy male volunteers, and healthy controls
Plasma concentrations of KYNA were markedly de-
creased in patients with MDD (23.8 nM, IQR 17.6–
31.8 nmol/L, n = 18) compared to KYNA levels in
healthy male volunteers (42.4 nmol/L, IQR 31.8–
51.2 nmol/L, n = 14; P < 0.0001, P [adjusted for age] =
0.001, Fig. 2d). An increased QUIN/KYNA ratio in
MDD (22.9, IQR 19.6–40.1, n = 18) compared to healthy
volunteers was also observed (14.4, IQR 11.8–19.4, n =
14; P < 0.001, P [adjusted for age] = 0.013, Fig. 2f ). In pa-
tients and in healthy controls, we did not observe anFig. 1 IL-6 (a), IL-8 (b), IL-10 (c), and tumor necrosis factor-α (TNF-α) (d) in t
point represents the concentration of a single plasma sample and the horiz
reported P value are two sided)effect of sex on either KYNA levels (P = 0.48 and P =
0.66, respectively) or the QUIN/KYNA ratio (P = 0.38,
only patients).
No differences in the plasma levels of tryptophan or
any of the other kynurenine metabolites (kynurenine,
QUIN, or the ratio of kynurenine/tryptophan) were de-
tected between patients with MDD and healthy volun-
teers (Fig. 2). Since the first control cohort included only
male volunteers and were significantly younger than
patients, plasma KYNA was measured in an age- and
gender-matched second cohort of controls. Plasma
KYNA was also here found to be significantly lower in
patients with MDD. Plasma KYNA levels in the second
cohort of controls were 40.6 nmol/L, IQR 33.0–
54.8 nmol/L (n = 22; P < 0.0001).Tryptophan metabolites and cytokines after treatment
with ECT in patients with MDD
Analysis of plasma tryptophan and kynurenine metabo-
lites after treatment with ECT in patients with MDD re-
vealed that plasma KYNA levels did not change but that
plasma levels of tryptophan, kynurenine, and QUIN sig-
nificantly decreased after three ECT (Fig. 3a, b, and e.)he plasma of patients with MDD (n = 18–19) and controls (n = 13). Each
ontal lines the median for each group. *P < 0.05 (Mann-Whitney U test,
Fig. 2 Tryptophan (a), kynurenine (b), kynurenine/tryptophan ratio (c), kynurenic acid (KYNA) (d), quinolinic acid (QUIN) (e), and QUIN/KYNA ratio
(f), in the plasma of healthy controls (n = 14) and patients with MDD (n = 19). Each point represents the concentration of a single plasma sample
and the horizontal lines the median for each group. ***P < 0.001 (Mann-Whitney U test) (all reported P values are two sided)
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three ECT treatments (P < 0.05, see Fig. 3f ).
The most pronounced effect of ECT was observed
with regard to plasma QUIN levels, which was found to
decrease in 80 % (12 out of 15) of the patients. No
changes in cytokine levels were found after three ECT
treatments (data not shown).
Correlation between kynurenine and MADRS score in
patients with MDD
Plasma kynurenine was found to negatively correlate to
MADRS score in patients with MDD before treatment with
ECT (ρ = −0.67; P = 0.002, Fig. 4a). This correlation was
not observed after three ECT administrations (ρ = −0.13;
P = 0.66, Fig. 4b). Neither did tryptophan nor any
other kynurenine metabolite or cytokine correlate to
the MADRS score before or after ECT. We could not
find any association between changes in the concen-
trations of tryptophan metabolites and the anti-
depressive response (data not shown).Discussion
In the present study, we investigated the peripheral con-
centration of cytokines and kynurenine metabolites in
unipolar patients diagnosed with an ongoing severe
major depressive episode. Our data, showing increased
plasma levels of IL-6, decreased KYNA levels, and an in-
creased QUIN/KYNA ratio in these patients, supports
the view of an ongoing low-grade inflammation [42] and
an imbalanced kynurenine pathway [30–33] in MDD.
The finding that the QUIN/KYNA ratio was increased
in patients supports the hypothesis of a netstimulation
of NMDA receptors in depression [30–33]. The observa-
tion of low plasma KYNA was confirmed in a second,
age- and gender-matched, healthy control cohort. Fur-
thermore, we found that treatment with ECT induced
major changes in peripheral kynurenine metabolites in
patients with MDD. Thus, plasma levels of tryptophan,
kynurenine, and QUIN significantly decreased after a
series of three ECT administrations whereas plasma
levels of KYNA did not change. Interestingly, following
Fig. 3 Tryptophan (a), kynurenine (b), kynurenine/tryptophan ratio (c), kynurenic acid (KYNA) (d), quinolinic acid (QUIN) (e), and QUIN/KYNA ratio
(f), in the plasma from unipolar depressed patients before and after three ECT treatments (n = 15). +P < 0.0.5; ++P < 0.01; +++P < 0.001 (Wilcoxon
matched-pairs signed-rank test, reported P values are two sided)
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80 % of all patients. In addition, ECT was associated
with a reduction in the QUIN/KYNA ratio, suggesting
that NMDA receptors are to a lesser extent stimulated.
In line with these findings, reduction in both CSF QUINFig. 4 Correlation between plasma kynurenine and total scores from Mont
treatment (a, n = 18) and after three ECT treatments (b, n = 15)levels and in the CSF QUIN/KYNA ratio has previously
been observed in suicide attempters following improve-
ment of their depressive symptoms [14].
In the present study, we found increased plasma levels
of IL-6 in patients with MDD. These results are in linegomery-Åsberg Depression Rating Scale (MADRAS) before ECT
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patients with depression [8, 12, 43]. It is well known that
pro-inflammatory cytokines, including IL-6, can induce
IDO, the rate-limiting enzyme of the kynurenine path-
way. Thus, injection of IL-6 into rat hippocampus is as-
sociated with the induction of IDO [19] and fetal human
cortical astrocytes respond to application of IL-6 with an
increased KYNA synthesis [20]. In line with this, we re-
cently found significantly positive correlation between
IL-6 and kynurenine metabolites in CSF, both in suicidal
attempters [14] as well as in patients with schizophrenia
[20], suggesting an intimate interplay between this cyto-
kine and the kynurenine pathway in the central nervous
system. However, in the present study, such a correlation
was not observed, indicating that this mechanism might
be brain specific.
In line with previous studies, we also here found low
levels of plasma KYNA in patients with MDD. Since re-
cent studies show that age and gender influence plasma
KYNA levels [44, 45], we included a second cohort of
age- and gender-matched healthy controls. Also com-
pared to this group, plasma KYNA was significantly de-
creased in patients with MDD. A challenging question is
why peripheral KYNA is decreased in depressed patients.
It has been suggested that a genetic variant in one of the
enzymes catalyzing the final step in the synthesis of
KYNA, kynurenine aminotransferase (KAT) III, is re-
sponsible [46]. Reduced expression or activity of the
KAT III enzyme might thus lead to diminished synthesis
of KYNA and consequently an imbalance between
KYNA and QUIN [14, 15, 32, 33, 46]. It was recently re-
ported that the total hippocampal and amygdala volume
in patients with MDD correlated with a reduced plasma
KYNA/QUIN ratio, indicating that an overweigh of the
toxic branch of the kynurenine pathway may be of im-
portance for the neurodegeneration occurring in these
patients [33]. The ability of ECT to significantly decrease
QUIN levels could thus be of clinical importance. In-
deed, a recent longitudinal ECT study shows that re-
peated ECT administration increases the levels of
KYNA, shifting the balance toward the neuroprotective
branch of the kynurenine pathway. Thus, serum levels of
KYNA and KYNA/3-HK increased over time with the
most pronounced effect on KYNA after 3 months [47].
In the present study, we did not observe any increase in
the plasma levels of KYNA, but since our study only
lasted for 2 weeks, longitudinal changes cannot be ex-
cluded. Conceivably, the mechanism of action of ECT
on patients with MDD could be due to its ability to
abate NMDA-receptor stimulation by decreasing the
levels of QUIN and/or strengthen NMDA-receptor an-
tagonism by increasing the levels of KYNA. Interestingly,
ketamine, an NMDA-receptor antagonist, has also been
reported to exert a rapid antidepressant effect in patientswith depression [48–50]. This effect of ketamine further
suggests that depression could be directly associated
with deficits in glutamatergic synaptic transmission.
In the present study, we also found a slight decrease of
plasma tryptophan after repeated ECT treatments in line
with a previous study [51]. Earlier studies, however, pro-
vide an inconsistent picture in this regard. Thus, un-
altered peripheral levels of tryptophan have been
reported in depressed patients after single or repeated
ECT administrations [47, 52, 53], whereas two other
studies showed increased plasma tryptophan levels after
ECT [54, 55]. The reason for the variability between
studies is not obvious but could be due to differences in
tryptophan measured (free or total), number of ECT
treatments, or time of sampling after the last ECT. It
has also been suggested that anesthesia used during
ECT could affect the plasma levels of tryptophan [53].
In line with a recent study [46], a negative correlation
between plasma kynurenine and depression scores was
observed. This might indicate that high levels of periph-
eral kynurenine are protective against depressive symp-
toms. Indeed, kynurenine can be effectively transported
over the blood-brain barrier (BBB) through the neutral
amino acid transporter. Approximately 60 % of brain
kynurenine is coming from peripheral sources, and in
the brain, kynurenine is transaminated to KYNA by the
KAT enzymes in astrocytes or to QUIN by kynurenine
3-monooxygenase (KMO) in microglial cells. Compared
to the higher capacity of KAT enzymes, displaying Km
values in the low milli-molar range [56], the KMO en-
zyme gets saturated at relatively low concentrations
(Km ≈ 20 μM) [57] and can therefore act as a rate-
limiting step in the synthesis of QUIN. High levels of
peripheral sources of kynurenine might, in this regard,
rather contribute to increased levels of brain KYNA,
which will guard against excessive NMDA-receptor
stimulation and increase the threshold for depressive
symptoms. In line with this hypothesis, we recently
found that CSF KYNA was negatively associated with
MADRS scores. Thus, the lower CSF KYNA, the worse
degree of depression and suicidal symptoms [15]. In
healthy volunteers, we recently detected a positive cor-
relation between plasma kynurenine and CSF KYNA
(unpublished observations), supporting the theory that
the plasma levels of kynurenine observed in the present
study reflect the central levels of KYNA in the patients.
In the present study, we observed that changes in the
plasma QUIN levels associated with ECT treatment but
not to the response of ECT as measured with MADRS.
This is in line with a earlier study in depressed patients
were CSF QUIN levels were found to correlate only to
total scores on the Suicide Intent Scale but not to the
mean score of MADRS or to the MADRS suicidality
item [14]. This may indicate that QUIN does not affect
Schwieler et al. Journal of Neuroinflammation  (2016) 13:51 Page 9 of 10depressive symptoms in general but rather has specific
effects on suicidal behavior. This may also explain why
we did not find any association between changes in the
concentrations of QUIN after ECT and the anti-
depressive response.
The results of the present study should be interpreted
in light of its limitations. Firstly, we only had excess to
plasma and not CSF, restricting our analysis to periph-
eral markers. Cytokines as well as the kynurenine me-
tabolites, KYNA and QUIN, do not easily pass the BBB,
and therefore, plasma levels of cytokines and kynure-
nines may not reflect changes in the brain. Secondly, for
ethical reasons, all patients were on different drug treat-
ments. Statistical corrections for drug treatment were
not eligible in this small cohort of patients, and there-
fore, we cannot fully rule out that the pharmacological
treatment did not influence contractions of cytokines or
kynurenines.
Conclusions
In conclusion, this study shows that ECT treatment re-
duces plasma QUIN levels in 80 % of the patients and
that the treatment was associated with a reduction in
the QUIN/KYNA ratio. Furthermore, we confirm previ-
ous studies showing decreased peripheral KYNA levels
and an increased QUIN/KYNA ratio in patients, sug-
gestive of a netstimulation of NMDA receptors in MDD.
Our findings strengthen the hypothesis that kynurenine
metabolites are key players in the pathophysiology of
MDD and the capacity of ECT to decrease the neuro-
toxic branch of the kynurenine pathway might therefore
be of clinical relevance.
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